The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
 
Alison R. Walker
Employment - Medtronic (I)
Honoraria - Patient Resource
Consulting or Advisory Role - Patient Resource
Research Funding - Geron; Newave Pharmaceutical; Novartis
Travel, Accommodations, Expenses - Gilead Sciences
 
Juan Miguel Bergua Burgues
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - Jazz Pharmaceuticals; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Sandoz
 
Pau Montesinos
Consulting or Advisory Role - BMSi; Novartis; SERVIER
Speakers' Bureau - Abbvie; BMSi; Jazz Pharmaceuticals; Sanofi; SERVIER; Teva
Research Funding - Abbvie; BMSi; Daiichi Sankyo
Travel, Accommodations, Expenses - Pfizer
 
Dale Bixby
Speakers' Bureau - Abbvie; BMSi; Jazz Pharmaceuticals; Sanofi; SERVIER; Teva
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead Sciences; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium Therapeutics; Trovagene
 
Marina Konopleva
Honoraria - Abbvie; Amgen; Amgen; Forty Seven; Genentech; KisoJi Biotechnology; Roche; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Amgen; Forty Seven; Genentech/Roche; Janssen; KisoJi Biotechnology; KisoJi Biotechnology; Roche; Stemline Therapeutics
Research Funding - Abbvie (Inst); Ablynx (Inst); Agios (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Forty Seven (Inst); Genentech (Inst); Lilly (Inst); Roche (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Eli LIlly- Research Funding; Issued/ Licensed; Novartis- PENDING; Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities); Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities)
 
Stephen Patrick Anthony
Employment - Newave Pharmaceutical; Sumitomo Dainippon Pharma
Leadership - Newave Pharmaceutical
Stock and Other Ownership Interests - Newave Pharmaceutical
Consulting or Advisory Role - Exact Sciences; Halia Therapeutics
Patents, Royalties, Other Intellectual Property - Sumitomo Dainippon Pharma Oncology
 
Fenlai Tan
Employment - Lupeng Pharmaceutical
Leadership - Lupeng Pharmaceutical
Stock and Other Ownership Interests - Lupeng Pharmaceutical
 
Yi Chen
Employment - Newave Pharmaceutical
Leadership - Newave Pharmaceutical
Stock and Other Ownership Interests - Newave Pharmaceutical
Honoraria - Newave Pharmaceutical
Research Funding - Newave Pharmaceutical
Patents, Royalties, Other Intellectual Property - Newave Pharmaceutical
Travel, Accommodations, Expenses - Newave Pharmaceutical
 
Yu Chen
Employment - Newave Pharmaceutical
Leadership - Newave Pharmaceutical
Stock and Other Ownership Interests - Newave Pharmaceutical
 
Yue Shen
Employment - Lupeng Pharmaceutical
Leadership - Lupeng Pharmaceutical
Stock and Other Ownership Interests - Lupeng Pharmaceutical
 
Patrick William Burke
Consulting or Advisory Role - Eisai (I); Lilly (I); Seagen (I)
Research Funding - Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - DAVA Pharmaceuticals